New Research Reports

Newsletter

About the stock: Siemens Energy India Ltd. (SEIL) is a leading player that provides technology and service in energy generation and transmission infrastructure. It has a comprehensive portfolio of products, solutions, and services designed to strengthen and expand grid infrastructure, addressing the growing demand while ensuring grid stability. Power transmission and power generation portfolio each contributed 50%...

Since inception the Company has delivered over 2.5 GW of module to domestic and international customers. It deploys range of technologies to fulfill diverse consumer needs, through a distribution network of 53 selling partners, including 23 resellers, 19 distributors and 11 channel partners.

MARKET SNAPSHOT

END OF DAY SUMMARY

Retail Research

company offers farmers an end-to-end single source solution for the survey, design, supply, assembly and installation, testing, commissioning and maintenance of solar-powered pump systems. The company is an empaneled vendor under the PM-KUSUM scheme in the states of Maharashtra, Haryana, Rajasthan, Uttar Pradesh and Madhya Pradesh with Maharashtra accounting for over 95% of SPPS installed by the company in F25. The company currently operates an asset-light model wherein it sources solar panels, pumps and various other components from different specialised vendors. Going forward,...

Company is an enterprise technology solutions specialist based out of India, offering comprehensive, purpose-built solutions for securing and managing digital applications and data. Company primarily serve large enterprises in their digital transformation by understanding their needs and working with System Integrators and OEMs to identify, recommend and deploy solutions meeting their requirements, aimed at ensuring performance, availability, scalability and security of digital applications and data. As per...

Aditya Birla Capital (ABCL) has steadily evolved into a digitally enabled, customer-focused financial services platform with a diversified presence spanning lending, insurance, and asset management.

The management maintains a long-term perspective on the business, aiming to navigate potential challenges and seize growth opportunities. We anticipate a steep revenue degrowth because of lower Revlimid sales in FY27. Focus will shift on the domestic formulations business with the anticipated launches of Semaglutide, which strengthens our case for...